ALK and lung carcinoma: Advances in molecular profiling and targeted therapy have shown that subgroups of lung cancer patients are highly sensitive to some small-molecule inhibitors targeting key molecular nodes that drive carcinogenesis in those patients, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK).